Committee hears bill to require fertility preservation coverage for certain cancer patients

Assemblymember Tanya Flanagan presented Assembly Bill 428 to the Assembly Committee on Commerce and Labor, proposing that certain public and private health plans in Nevada include coverage for fertility preservation services when an insured has been diagnosed with breast or ovarian cancer or is expected to receive medical treatment that could directly or indirectly cause infertility.

Flanagan opened by describing fertility preservation as a critical option for cancer patients facing treatments such as chemotherapy and radiation that can impair reproductive ability. She said cost barriers often prevent patients from pursuing preservation and cited national data on treatment impact and cost. Dr. Stephanie Christiansen, a board-certified hematologist/oncologist practicing in Henderson and Las Vegas, testified in strong support and described clinical guidance: the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology advise clinicians to inform premenopausal patients about fertility risks and offer referrals for preservation when future childbearing is desired.

Flanagan summarized the bill's provisions on coverage scope: sections would require public and private plans, including Medicaid and state and local government employee plans, to provide coverage for procedures deemed medically necessary to preserve fertility for insureds diagnosed with breast or ovarian cancer when (1) the cancer may directly or indirectly cause infertility, or (2) the insured is expected to receive treatment that could cause infertility. The bill allows an insurer affiliated with a religious organization to opt out if it objects on religious grounds and discloses that in writing. The bill also authorizes the Commissioner of Insurance to require individual policies by domestic insurers issued to nonresidents to include the coverage, and authorizes suspension or revocation of a certificate of authority for HMO or insurer noncompliance.

Committee members asked for data on how many Nevada families would be affected. Dr. Christiansen and the sponsor cited a U.S. figure of roughly 268,000 annual invasive breast-cancer diagnoses nationwide and estimated that about 320 Nevada women who are premenopausal are diagnosed annually; Flanagan and the doctor clarified that the pool of patients who would seek fertility preservation is smaller (medical factors, age and whether patients already have children influence uptake), with medical practitioners estimating roughly 30% to 50% of eligible patients seek a reproductive-endocrinology consultation in their experience.

Stakeholder testimony included supportive statements from the ACLU of Nevada and Planned Parenthood Votes Nevada and a remote speaker from the Alliance for Fertility Preservation, which voiced support but urged the committee to consider a broader scope to include all cancer patients whose treatment threatens fertility (including pediatric and young-adult patients). Clark County and the Nevada Association of Health Plans testified in neutral positions, thanking the sponsor for engagement and asking to work on age parameters and other guardrails to address affordability. Adam Plain, Insurance Regulation Liaison for the Nevada Division of Insurance, said the division is neutral as a matter of policy and noted the division's fiscal analysis determined the bill would trigger federal defrayal for the individual market; the division submitted a fiscal note with calculations.

Committee members pressed on coverage limits: Flanagan said the draft does not yet specify cycle limits, lifetime maximums or specific storage-year limits and that those policy specifics remain under discussion with stakeholders. Members also asked about embryo storage legal issues and duration; Dr. Christiansen said reproductive endocrinologists often recommend egg (oocyte) cryopreservation rather than embryo creation initially, to avoid custody issues that can arise if personal relationships change; she emphasized the clinical distinction between unfertilized eggs and embryos.

Sponsor Flanagan closed by repeating her personal experience as a cancer survivor and urging lawmakers to consider the financial and emotional burdens on patients who lack coverage for fertility-preservation services. The committee did not take a vote at the hearing; the hearing record closed and the committee moved on to subsequent bills. Stakeholders and the sponsor indicated continuing negotiations on specific coverage parameters, storage periods and possible guardrails to limit actuarial impact.

Votes or formal actions were not taken during the hearing; the hearing record includes support, neutral and support-with-reservations testimony and questions for staff and the Division of Insurance.